Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29903006 | 1.00 | MAPK1 (0.51) | MAPK1POLBRAB9ATDP1SMN1; SMN2 | |
| SCHEMBL20339548 | 0.90 | KDM4E (0.51) | MAPK1POLBRAB9ATDP1SMN1; SMN2 | |
| SCHEMBL29902945 | 0.90 | KDM4E (0.51) | MAPK1POLBRAB9ATDP1SMN1; SMN2 | |
| SCHEMBL23073618 | 0.86 | MAPK1 (0.38) | MAPK1POLBRAB9AHTTALDH1A1 | |
| SCHEMBL21794443 | 0.85 | ALDH1A1 (0.50) | POLBHTTALDH1A1HPGDHSD17B10 | |
| SCHEMBL29902966 | 0.82 | KMT2A (0.55) | MAPK1POLBTDP1KDM4EALDH1A1 | |
| SCHEMBL20339628 | 0.82 | KMT2A (0.55) | MAPK1POLBTDP1KDM4EALDH1A1 | |
| SCHEMBL3130610 | 0.81 | RAB9A (0.68) | POLBRAB9ATDP1SMN1; SMN2HTT | |
| SCHEMBL15574660 | 0.80 | TP53 (0.42) | POLBRAB9AALDH1A1HSD17B10KMT2A | |
| SCHEMBL15575684 | 0.80 | L3MBTL1 (0.57) | MAPK1SMN1; SMN2KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993585-B2 | Poly-ADP ribose polymerase (PARP) inhibitors | MITOBRIDGE, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| CN-110167926-B | Poly-ADP ribose polymerase (PARP) inhibitors | 米托布里奇公司 | 2022-09-13 | — | — | CN | disclosed |
| US-20220033380-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2022-02-03 | — | — | US | disclosed |
| US-20220033380-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2022-02-03 | — | — | US | disclosed |
| US-11034670-B2 | Poly-ADP ribose polymerase (PARP) inhibitors | MITOBRIDGE, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-11034670-B2 | Poly-ADP ribose polymerase (PARP) inhibitors | MITOBRIDGE, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| EP-3562822-B1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | MITOBRIDGE INC (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3562822-B1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | MITOBRIDGE INC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20200071299-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2020-03-05 | — | — | US | disclosed |
| US-20200071299-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2020-03-05 | — | — | US | disclosed |
| EP-3562822-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | Mitobridge, Inc. (US) | 2019-11-06 | — | — | EP | disclosed |
| WO-2018125961-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | MITOBRIDGE, INC. (US) | 2018-07-05 | — | — | WO | disclosed |
| WO-2018125961-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | MITOBRIDGE, INC. (US) | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033380-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP11 | MAPK1 3745/4885POLB 28/4885RAB9A 3951/4885 |
| US-11993585-B2 | Poly-ADP ribose polymerase (PARP) inhibitors | PARP1, PARP2, PARP11 | MAPK1 3745/4885POLB 28/4885RAB9A 3951/4885 |
| US-11034670-B2 | Poly-ADP ribose polymerase (PARP) inhibitors | PARP1, PARP2, PARP11 | MAPK1 3745/4885POLB 28/4885RAB9A 3951/4885 |
| US-20200071299-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP11 | MAPK1 3745/4885POLB 28/4885RAB9A 3951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.